Volume : 08, Issue : 08, August – 2021
Title:
42.DESIGN AND EVALUATION OF ORODISPERSABLE TABLETS OF ESOMEPRAZOLE
Authors :
T. Balakrishna, S. Vidyadhara, M. Shalini, M.Vineetha chowdary, N.Divyasri, A.Susmitha, G.Yeseswi Archana
Abstract :
The present research work is mainly focused on design and evaluation of orodispersable tablets of esomeprazole, which are used for the treatment of gastro esophageal reflux disease. An attempt was made to increase the solubility and dissolution rate of esomeprazole by formulating it as solid dispersions by physical method, kneading method and solvent evaporation method. Later the optimized solid dispersions were further formulated into orodispersable tablets using superdisintegrants such as Crosmellose sodium & crospovidone by direct compression technique. Characterization studies were carried out by pure drug (Esomeprazole) superdisintegrants (Croscarmellose sodium & Crospovidone) and optimized formulation E6 by FTIR and DSC Studies. The Studies were shown that there was no drug and excipient interaction. Based on the study, it may be concluded that esomeprazole tablets prepared by using optimized solid dispersions (ES2) with Soluplus & Croscarmellose sodium as superdisintegrant was found to be ideal for rapid dispersion and for improving dissolution rate, which in turn increases the bioavailability.
Key words: Solid dispersions Oro dispersible tablets, Esomeprazole, Soluplus, Croscarmellose sodium and crospovidone.
Cite This Article:
Please cite this article in press T.Balakrishna et al., Design And Evaluation Of Orodispersable Tablets Of Esomeprazole ., Indo Am. J. P. Sci, 2021; 08(08).
Number of Downloads : 10
References:
1. Tejvir Kaur p, a Mouth dissolving tablets. International journal of current pharmaceutical research. 3: 42-50. 2003
2. Yang S, Jeong SH, Kimura S, Park K. Orally fast disintegrating tablets. Crit Rev Ther Dreg Carrier Syst. 2004; 21: 433–446.
3. Hassan-Alin M, Andersson T, Bredgerg E, Röhss K. Eur J Clin Pharmacol. 2000; 56: 665–670.
4. Swan SK, Hoyumpa AM, Merritt GJ. Aliment Pharmacol Ther; 1999; 13:11–17.
5. Lassen AT. Acid-related disorders and use of antisecretory medication. Dan Med Bull. 2007; 54: 18–30.
6. Shi S, Klotz U. Proton pump inhibitors: an update of their clinical use and pharmacokinetics. Eur J Clin Pharmacol. 2008; 64: 935–9517.
7. Klotz U. Pharmacokinetic considerations in the eradication of Helicobacter pylori. Clin Pharmacokinet. 2000; 38: 243–270.
8. Muhrer G, Meier U, Fusaro F, Albano S, Mazzotti M. Int J Pharm. 2006; 308:69-80.
9. Guyot M, Fawaz F, Bonini JF, Lagueny AM Int J Pharm. 1995; 123: 53-63.
10. Zoeller Thomas, Dressman Jennifer B, Klein Sandra Int J Pharm. 2012; 430: 176–183.
11. Balakrishna T, Vidyadhara S, Murthy T. E. G. K, Sasidhar RLC, Vikas S. Formulation and evaluation of lansoprazole orodispersable tablets using novel excipients. Der Pharmacia Lettre. 2016; 8 17:73-82.